Promazine hydrochloride
Promazine is a low-potency phenothiazine antipsychotic used mainly for the short-term management of agitation and restlessness, particularly in elderly patients.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks central dopamine D2 receptors and also antagonises histamine, muscarinic and alpha-adrenergic receptors, giving it strong sedative and autonomic effects relative to its antipsychotic potency.
Prescribing in practice
- Sedation and postural hypotension are prominent, increasing the risk of falls in elderly patients who should be treated cautiously.
- Antipsychotics are associated with an increased risk of stroke and mortality when used for behavioural symptoms in elderly people with dementia.
- It carries the class risks of QT prolongation, extrapyramidal effects and neuroleptic malignant syndrome, with caution needed in cardiovascular and hepatic disease.
Monitoring
Monitor sedation, postural blood pressure, fall risk and for extrapyramidal or neuroleptic malignant features during treatment.
Counselling the patient
- This medicine is likely to make you drowsy; do not drive or use machinery until you know how it affects you.
- Get up slowly from sitting or lying to reduce dizziness.
- Avoid alcohol, which increases drowsiness.
Evidence & guidelines
Caution with antipsychotics in elderly and dementia patients is highlighted by MHRA and NICE guidance on increased stroke and mortality risk.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185